FDA Finalizes Guidance on Evaluating Drug Effects on Driving Ability

Clinical Trials Advisor
The FDA published guidance assisting sponsors in evaluating the effects of psychoactive drugs on the ability to operate a motor vehicle. The agency recommends a tiered approach to evaluating drug effects, consisting of pharmacology/toxicology, epidemiology and clinical behavioral assessments. Data obtained early in development can be used to guide the collection of subsequent data related to driving impairment, for a better allocation of sponsor resources.

To View This Article:


Subscribe To Clinical Trials Advisor